Fox Run Management L.L.C. purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 4,635 shares of the biotechnology company's stock, valued at approximately $667,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Signaturefd LLC raised its holdings in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the period. Resources Management Corp CT ADV bought a new position in Repligen in the 3rd quarter valued at $37,000. Quarry LP increased its stake in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 239 shares during the period. UMB Bank n.a. lifted its position in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its stake in shares of Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 129 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other Repligen news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.20% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on RGEN shares. TD Cowen started coverage on shares of Repligen in a report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. StockNews.com downgraded shares of Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. Royal Bank of Canada increased their price objective on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. Finally, Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $178.64.
Check Out Our Latest Analysis on Repligen
Repligen Stock Performance
Shares of Repligen stock opened at $145.15 on Tuesday. Repligen Co. has a one year low of $113.50 and a one year high of $198.00. The company has a market capitalization of $8.15 billion, a PE ratio of -284.61, a P/E/G ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a 50-day simple moving average of $155.91 and a two-hundred day simple moving average of $148.40.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Research analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
